Exelixis Inc. Common Stock (EXEL)
Stock · NASDAQ · Health Care
$62.23as of 10/16/2026
Price chart
Active signals
EXEL Signal Track Record
How signals performed across all stocks →What EXEL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +2.2% | 61% | September 8, 2026 |
| Bollinger Band Breakout | 26 | +4.3% | 58% | October 9, 2026 |
| Bollinger Band Breakdown | 21 | +3.8% | 76% | July 31, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +4.1% | 79% | March 27, 2026 |
| Any 20-session window (baseline) | +2.3% | 61% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EXEL
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOME…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 1,077
- Website
- www.exelixis.com/
Fundamentals
- 1-day range
- $59.9$61.66
- Market cap
- $13.12B
- P/E (trailing)
- 17.49
- P/E (forward)
- 14.23
- EPS (trailing)
- $3.18
- Dividend yield
- —
- Beta
- 0.44
- Avg. volume
- 2.33M
How Exelixis Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Exelixis Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EXELExelixis Inc. Common Stock$62.23▼ 0.95%Market cap $13.12BP/E 17.49$33.76$61.66
- HALOHalozyme Therapeutics Inc. Common Stock$121.84▲ 0.27%Market cap $10.17BP/E 32.51$61.23$119.21
- NBIXNeurocrine Biosciences Inc. Common Stock$135.71▼ 0.91%Market cap $16.25BP/E 19.57$122.14$186.12
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EXEL Exelixis Inc. Common Stock | $13.12B | 17.49 | $62.23 | ▼ 0.95% | $33.76$61.66 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 32.51 | $121.84 | ▲ 0.27% | $61.23$119.21 |
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 19.57 | $135.71 | ▼ 0.91% | $122.14$186.12 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?Yahoo · 9/24/2026
- Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?Yahoo · 9/22/2026
- Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal CancerYahoo · 9/21/2026
- Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3BYahoo · 9/17/2026
- Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?Yahoo · 9/17/2026
- Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp HurdleYahoo · 9/15/2026
- Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)SeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Mary C. Beckerle · August 10, 2026 · Sale9.8K @ $53.66
- Sue Gail Eckhardt · June 1, 2026 · Sale9.8K @ $50.14
- Jack L. Wyszomierski · June 1, 2026 · Sale3.9K @ $50.55
- Sue Gail Eckhardt · May 27, 2026 · Grant8.4K
- Tomas J. Heyman · May 27, 2026 · Grant8.4K
- Stelios Papadopoulos · May 27, 2026 · Grant8.4K
- George Poste · May 27, 2026 · Grant8.4K
- Jack L. Wyszomierski · May 27, 2026 · Grant8.4K
- Caligan Partners LP · May 27, 2026 · Grant19.1K
- Bob Oliver · May 27, 2026 · Grant8.4K
- Julie Smith · May 27, 2026 · Grant8.4K
- Maria C. Freire · May 27, 2026 · Grant8.4K
- Mary C. Beckerle · May 27, 2026 · Grant8.4K
- Dana Aftab · May 26, 2026 · Sale43.5K @ $50.35
- Patrick J. Haley · May 20, 2026 · Sale32.1K @ $49.81
Institutional Ownership
March 31, 2026
- Total shares held
- 244.03M
- Total value held
- $9.88B
- Institutional holders
- 687
- Unknown30.82M
- Unknown13.73M
- Unknown13.11M
- Unknown13.10M
- Unknown11.26M
- Unknown10.30M
- Unknown8.54M
- Unknown7.80M
- Unknown7.75M
- Unknown4.83M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue
Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.